Literature DB >> 30089827

Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis.

Philip Farrell1, Claude Férec2,3, Milan Macek4, Thomas Frischer5, Sabine Renner5, Katharina Riss5, David Barton6,7, Teresa Repetto8, Maria Tzetis9, Karine Giteau3, Morten Duno10, Melissa Rogers6, Hara Levy11, Mourad Sahbatou12, Yann Fichou2, Cédric Le Maréchal2,3, Emmanuelle Génin2.   

Abstract

The high incidence of cystic fibrosis (CF) is due to the frequency of the c.1521_1523delCTT variant in the cystic fibrosis transmembrane conductance regulator (CFTR), but its age and origin are uncertain. This gap limits attempts to shed light on the presumed heterozygote selective advantage that accounts for the variant's high prevalence among Caucasian Europeans and Europe-derived populations. In addition, explaining the nature of heterozygosity to screened individuals with one c.1521_1523delCTT variant is challenging when families raise questions about these issues. To address this gap, we obtained DNA samples from 190 patients bearing c.1521_1523delCTT and their parents residing in geographically distinct European populations plus a Germany-derived population in the USA. We identified microsatellites spanning CFTR and reconstructed haplotypes at 10 loci to estimate the time/age of the most recent common ancestor (tMRCA) with the Estiage program. We found that the age estimates differ between northwestern populations, where the mean tMRCA values vary between 4600 and 4725 years, and the southeastern populations where c.1521_1523delCTT seems to have been introduced only about 1000 years ago. The tMRCA values of Central Europeans were intermediate. Thus, our data resolve a controversy by establishing an early Bronze Age origin of the c.1521_1523delCTT allele and demonstrating its likely spread from northwest to southeast during ancient migrations. Moreover, taking the archeological record into account, our results introduce a novel concept by suggesting that Bell Beaker folk were the probable migrating population responsible for the early dissemination of c.1521_1523delCTT in prehistoric Europe.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30089827      PMCID: PMC6244163          DOI: 10.1038/s41431-018-0234-z

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  27 in total

1.  Estimating the age of rare disease mutations: the example of Triple-A syndrome.

Authors:  E Genin; A Tullio-Pelet; F Begeot; S Lyonnet; L Abel
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  CFTR mutation analysis and haplotype associations in CF patients.

Authors:  S K Cordovado; M Hendrix; C N Greene; S Mochal; M C Earley; P M Farrell; M Kharrazi; W H Hannon; P W Mueller
Journal:  Mol Genet Metab       Date:  2011-10-26       Impact factor: 4.797

3.  Investigation of the fine structure of European populations with applications to disease association studies.

Authors:  Simon C Heath; Ivo G Gut; Paul Brennan; James D McKay; Vladimir Bencko; Eleonora Fabianova; Lenka Foretova; Michael Georges; Vladimir Janout; Michael Kabesch; Hans E Krokan; Maiken B Elvestad; Jolanta Lissowska; Dana Mates; Peter Rudnai; Frank Skorpen; Stefan Schreiber; José M Soria; Ann-Christine Syvänen; Pierre Meneton; Serge Herçberg; Pilar Galan; Neonilia Szeszenia-Dabrowska; David Zaridze; Emmanuel Génin; Lon R Cardon; Mark Lathrop
Journal:  Eur J Hum Genet       Date:  2008-12       Impact factor: 4.246

4.  Correlation between genetic and geographic structure in Europe.

Authors:  Oscar Lao; Timothy T Lu; Michael Nothnagel; Olaf Junge; Sandra Freitag-Wolf; Amke Caliebe; Miroslava Balascakova; Jaume Bertranpetit; Laurence A Bindoff; David Comas; Gunilla Holmlund; Anastasia Kouvatsi; Milan Macek; Isabelle Mollet; Walther Parson; Jukka Palo; Rafal Ploski; Antti Sajantila; Adriano Tagliabracci; Ulrik Gether; Thomas Werge; Fernando Rivadeneira; Albert Hofman; André G Uitterlinden; Christian Gieger; Heinz-Erich Wichmann; Andreas Rüther; Stefan Schreiber; Christian Becker; Peter Nürnberg; Matthew R Nelson; Michael Krawczak; Manfred Kayser
Journal:  Curr Biol       Date:  2008-08-07       Impact factor: 10.834

5.  Age of the delta F508 cystic fibrosis mutation.

Authors:  N L Kaplan; P O Lewis; B S Weir
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

6.  Population genomics of Bronze Age Eurasia.

Authors:  Morten E Allentoft; Martin Sikora; Karl-Göran Sjögren; Simon Rasmussen; Morten Rasmussen; Jesper Stenderup; Peter B Damgaard; Hannes Schroeder; Torbjörn Ahlström; Lasse Vinner; Anna-Sapfo Malaspinas; Ashot Margaryan; Tom Higham; David Chivall; Niels Lynnerup; Lise Harvig; Justyna Baron; Philippe Della Casa; Paweł Dąbrowski; Paul R Duffy; Alexander V Ebel; Andrey Epimakhov; Karin Frei; Mirosław Furmanek; Tomasz Gralak; Andrey Gromov; Stanisław Gronkiewicz; Gisela Grupe; Tamás Hajdu; Radosław Jarysz; Valeri Khartanovich; Alexandr Khokhlov; Viktória Kiss; Jan Kolář; Aivar Kriiska; Irena Lasak; Cristina Longhi; George McGlynn; Algimantas Merkevicius; Inga Merkyte; Mait Metspalu; Ruzan Mkrtchyan; Vyacheslav Moiseyev; László Paja; György Pálfi; Dalia Pokutta; Łukasz Pospieszny; T Douglas Price; Lehti Saag; Mikhail Sablin; Natalia Shishlina; Václav Smrčka; Vasilii I Soenov; Vajk Szeverényi; Gusztáv Tóth; Synaru V Trifanova; Liivi Varul; Magdolna Vicze; Levon Yepiskoposyan; Vladislav Zhitenev; Ludovic Orlando; Thomas Sicheritz-Pontén; Søren Brunak; Rasmus Nielsen; Kristian Kristiansen; Eske Willerslev
Journal:  Nature       Date:  2015-06-11       Impact factor: 49.962

Review 7.  Beta-globin gene haplotypes among cameroonians and review of the global distribution: is there a case for a single sickle mutation origin in Africa?

Authors:  Valentina J Ngo Bitoungui; Gift D Pule; Neil Hanchard; Jeanne Ngogang; Ambroise Wonkam
Journal:  OMICS       Date:  2015-03

8.  Complete map of cystic fibrosis mutation DF508 frequencies in Western Europe and correlation between mutation frequencies and incidence of disease.

Authors:  G Lucotte; S Hazout; M De Braekeleer
Journal:  Hum Biol       Date:  1995-10       Impact factor: 0.553

9.  Estimating the age of CFTR mutations predominantly found in Brittany (Western France).

Authors:  Yann Fichou; Emmanuelle Génin; Cédric Le Maréchal; Marie-Pierre Audrézet; Virginie Scotet; Claude Férec
Journal:  J Cyst Fibros       Date:  2007-09-06       Impact factor: 5.482

10.  Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis.

Authors:  Charles M Strom; Beryl Crossley; Arlene Buller-Buerkle; Michael Jarvis; Franklin Quan; Mei Peng; Kasinathan Muralidharan; Victoria Pratt; Joy B Redman; Weimin Sun
Journal:  Genet Med       Date:  2011-02       Impact factor: 8.822

View more
  21 in total

1.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

2.  Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Authors:  Sherie Smith; Valerie Waters; Nikki Jahnke; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

3.  Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Kate H Regan; Jayesh Bhatt
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

Review 4.  Short-acting inhaled bronchodilators for cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Christopher T Edwards
Journal:  Cochrane Database Syst Rev       Date:  2022-06-24

Review 5.  Exercise versus airway clearance techniques for people with cystic fibrosis.

Authors:  Katie D Heinz; Adam Walsh; Kevin W Southern; Zoe Johnstone; Kate H Regan
Journal:  Cochrane Database Syst Rev       Date:  2022-06-22

6.  Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Sherie Smith; Felix Ratjen; Tracey Remmington; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2020-05-15

7.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Linsey Abbott; Amanda Plummer; Zhe Hui Hoo; Martin Wildman
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05

8.  Ethnic Differences in the Frequency of CFTR Gene Mutations in Populations of the European and North Caucasian Part of the Russian Federation.

Authors:  Nika Petrova; Natalia Balinova; Andrey Marakhonov; Tatyana Vasilyeva; Nataliya Kashirskaya; Varvara Galkina; Evgeniy Ginter; Sergey Kutsev; Rena Zinchenko
Journal:  Front Genet       Date:  2021-06-16       Impact factor: 4.599

9.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

Authors:  Poppy Holland; Nikki Jahnke
Journal:  Cochrane Database Syst Rev       Date:  2021-06-23

Review 10.  Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.

Authors:  Christabella Ng; Giles Major; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.